555win cung cấp cho bạn một cách thuận tiện, an toàn và đáng tin cậy [kqxs 30 ngay]
Feb 26, 2024 · In the present study, we examined the potential of pronecroptotic therapy using CNLs for refractory triple-negative breast cancer (TNBC), for which there is a lack of definite …
Jan 1, 2012 · Recent lipidomic analyses have demonstrated that specific ceramide species are differentially metabolized in individual cancers. Therapeutics that increase ceramide levels in …
Feb 26, 2024 · Journals Cells Volume 13 Issue 5 10.3390/cells13050405 Version Notes Review for this Journal
Sep 22, 2023 · Purpose: Ceramide is a sphingolipid metabolite that deactivates multiple oncogenic signaling pathways and promotes cell death. In-vivo data demonstrate single-agent …
Using the ceramide nanoliposomes (CNL), we now investigate the therapeutic efficacy and signaling mechanisms of this nanoscale delivery platform in refractory ovarian cancer. …
The up-regulation of MLKL is presumed to sensitize cancer cells to necroptotic cell death, and pronecroptotic therapy is potentially effective for cancer cells that highly express MLKL.
Integration of C₆-ceramide into stealth pegylated nanoliposomes has led to the development of a promising preclinical therapeutic alone and in combination with other agents for treatment of …
Feb 26, 2024 · In the present study, we examined the potential of pronecroptotic therapy using CNLs for refractory triple-negative breast cancer (TNBC), for which there is a lack of definite …
Ceramide synthase 2-C24:1 -ceramide axis limits the metastatic potential of ovarian cancer cells.
It is concluded that selective inhibition of the glycolytic pathway in CLL cells with nanoliposomal C6-ceramide could potentially be an effective therapy for leukemia by targeting the Warburg …
Bài viết được đề xuất: